INT6103

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.50
First Reported 1988
Last Reported 1997
Negated 0
Speculated 0
Reported most in Abstract
Documents 5
Total Number 5
Disease Relevance 0.61
Pain Relevance 4.83

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Cck) extracellular region (Cck)
Anatomy Link Frequency
ventromedial hypothalamic nucleus 2
nucleus 2
dopaminergic neurons 2
Cck (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Cholecystokinin 39 100.00 Very High Very High Very High
narcan 7 99.84 Very High Very High Very High
Analgesic 4 99.48 Very High Very High Very High
Neuropeptide 3 98.92 Very High Very High Very High
Opioid 4 98.38 Very High Very High Very High
Substantia nigra 2 97.72 Very High Very High Very High
Dopamine 1 97.72 Very High Very High Very High
antagonist 6 96.46 Very High Very High Very High
analgesia 5 96.08 Very High Very High Very High
opiate 8 96.06 Very High Very High Very High
Disease Link Frequency Relevance Heat
Pressure Volume 2 Under Development 1 87.32 High High
Volume Depletion And Dehydration 1 86.80 High High
Pain 3 80.12 Quite High
Hyperalgesia 1 79.60 Quite High
Cognitive Disorder 1 71.88 Quite High
Anxiety Disorder 1 71.00 Quite High
Urological Neuroanatomy 1 41.80 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We observed in these regions that cholecystokinin and tyrosine hydroxylase mRNAs coexisted in the same neurons but not all dopamine cells expressed cholecystokinin mRNA. 6-Hydroxydopamine-induced destruction of mesostriatal dopaminergic neurons resulted in a complete loss of cholecystokinin and tyrosine hydroxylase mRNA expression throughout the substantia nigra pars compacta, indicating that all cholecystokinin expressing cells are 6-hydroxydopamine-sensitive.
Positive_regulation (resulted) of Negative_regulation (loss) of cholecystokinin in dopaminergic neurons associated with dopamine, substantia nigra and cholecystokinin
1) Confidence 0.50 Published 1989 Journal Neuroscience Section Abstract Doc Link 2566954 Disease Relevance 0 Pain Relevance 0.68
On the basis of the discovery of the anti-opioid action of the neuropeptide cholecystokinin, recent studies demonstrate that the blockade of cholecystokinin receptors potentiates the placebo analgesic response, thus suggesting an inhibitory role of cholecystokinin in placebo analgesia.
Positive_regulation (potentiates) of Negative_regulation (blockade) of cholecystokinin associated with analgesic, neuropeptide, cholecystokinin, opioid and analgesia
2) Confidence 0.49 Published 1997 Journal Prog. Neurobiol. Section Abstract Doc Link 9185235 Disease Relevance 0.43 Pain Relevance 1.83
Brain stem-projecting oxytocin (OT) neurons in the hypothalamic paraventricular nucleus (PVN) have been proposed to mediate the inhibitory effects of CCK and LiCl on gastric motility and food intake.
Positive_regulation (mediate) of Negative_regulation (effects) of CCK in nucleus associated with cholecystokinin
3) Confidence 0.41 Published 1992 Journal Am. J. Physiol. Section Abstract Doc Link 1322067 Disease Relevance 0 Pain Relevance 0.35
Moreover, the inhibitory effects of CCK and LiCl on gastric motility and feeding similarly were enhanced by naloxone.
Positive_regulation (enhanced) of Negative_regulation (effects) of CCK associated with narcan and cholecystokinin
4) Confidence 0.41 Published 1988 Journal Neuroendocrinology Section Abstract Doc Link 2855107 Disease Relevance 0.17 Pain Relevance 0.64
The universal opiate receptor antagonist naltrexone and the delta-opiate receptor antagonist naltrindole each potentiated the estrogen-induced increase and elevated cholecystokinin messenger RNA levels an additional 1.9- to 2.8-fold depending on the nucleus examined, but had no effect on the estrogen-induced expression of either preproenkephalin or preprotachykinin messenger RNA. beta-Funaltrexamine, a mu-opiate receptor antagonist, had no effect on the medial preoptic or medial amygdaloid cholecystokinin messenger RNA levels or on the estrogen-induced expression of preproenkephalin messenger RNA but did cause a decrease in estrogen-induced cholecystokinin messenger RNA levels in the bed nucleus of the stria terminalis and a decrease in the preprotachykinin messenger RNA levels in the ventromedial hypothalamic nucleus.
Positive_regulation (cause) of Negative_regulation (decrease) of cholecystokinin in ventromedial hypothalamic nucleus associated with antagonist, opiate and cholecystokinin
5) Confidence 0.38 Published 1997 Journal Neuroscience Section Abstract Doc Link 9284350 Disease Relevance 0 Pain Relevance 1.33

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox